R & D Focus Drug News reported that GSK began phase I trials of the compound for the treatment of hyperlipidemia in 2000 followed by phase I/II in 2002.
Wie R&D Focus Drug News berichtete, begann GSK im Jahr 2000 Phase I Tests des Mittels zur Behandlung von Hyperlipoproteinämie, gefolgt von Phase I/II Tests im Jahr 2002.